Sangamo Therapeutics Reports $31M Q1 Net Loss, $1.4M Revenue; Cash Runway into Q3 2026 Amid Nasdaq Delisting
SGMO sits 36% above its 52-week low of $0.1 on light trading volume (0.2× avg).
Summary
Sangamo Therapeutics reported a substantial Q1 2026 net loss of $31.0 million against minimal revenues of $1.4 million. The company's cash and cash equivalents have dwindled to $27.6 million as of March 31, 2026, with management indicating this cash will only sustain operations into the third quarter of 2026. This extremely short cash runway, combined with significant quarterly burn, signals an urgent need for financing and raises going concern risks. Compounding these financial challenges, Sangamo recently moved to the OTCQB Venture Market and is actively appealing a Nasdaq delisting decision, with a hearing set for June 9, 2026. These corporate governance issues severely impact the company's market standing and investor confidence, largely overshadowing any clinical progress, such as the ongoing rolling BLA submission for ST-920. Traders should monitor the outcome of the Nasdaq appeal and any potential capital raises closely.
At the time of this announcement, SGMO was trading at $0.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.1M. The 52-week trading range was $0.10 to $0.77. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.